Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb Co. on Dec. 18 took another step in narrowing its therapeutic focus by selling its pipeline of HIV candidates, including novel Phase III and Phase IIb assets, to ViiV Healthcare in a pair of deals bringing $350m in upfront cash and significant earn-out potential back to the US-based pharma.

You may also be interested in...



How Will Novel Agents Impact The HIV Market?

ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research. 

Bristol Changes Up R&D But Not Backing Down On Oncology

The appointment of oncologist Thomas Lynch to succeed Francis Cuss as Chief Scientific Officer suggests the biopharma won’t be straying too far from its current focus on developing cancer drugs.

Novel Antibody Products Ring The Treatment Changes In HIV

Two Canadian companies – Theratechnologies and CytoDyn – exploring the use of monoclonal antibodies in the fight against HIV presented data for their novel late-stage candidates at the recent CROI meeting in Seattle. They are aimed at patients experiencing multi-drug resistance and represent a change in this mature therapy area dominated by small-molecule oral products.

Related Content

Topics

UsernamePublicRestriction

Register

SC064036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel